1194MO Canakinumab

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or ...

Preclinical data with CAN, a selective interleukin-1β inhibitor, plus DTX showed greater tumor growth reduction than DTX alone and decreased immunosuppressive ...

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second

Financial Interests, Personal, Other, honoraria: Boehringer Ingelheim, Roche, MSD, AstraZeneca,. Novartis, Bristol Myers Squibb, Ono Pharmaceuticals, ...

Repositioning canakinumab for non-small cell lung cancer ... - NCBI

... canakinumab-lung-cancer (accessed October 29, 2021). 2. Paz-Ares L, Goto Y, Lim WDT, Halmos B, Cho BC, Dols MC, et al. 1194MO Canakinumab ...

ESMO Congress 2021 | OncologyPRO

Miranda Gogishvili. Session: Mini oral session - NSCLC, metastatic. Resources: Abstract. Slides. Webcast. 19 Sep 2021. 1194MO - Canakinumab (CAN) + docetaxel ( ...

or third-line (2/3L) treatment of advanced non-small cell lung cancer ...

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III ...

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or ...

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III ...

ESMO Congress 2021 | OncologyPRO

1194MO - Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase ...

Canakinumab Combo Misses Survival End Points in Previously ...

Canakinumab plus pembrolizumab and platinum-based doublet ... Paz-Ares L, Goto Y, Lim WDT, et al. 1194MO canakinumab (CAN) + ...

ESMO 2021: [VIRTUAL] Canakinumab (CAN) + docetaxel (DTX) for ...

1194MO - [VIRTUAL] Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY ...

A multicenter, randomized, double-blind, phase 3 trial - PubMed

Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based ...

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or ...

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III ...

ESMO 2021: Recommendations From Dr. Sarah Goldberg

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): ...

Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

Canakinumab (Ilaris), a selective IL-1β inhibitor approved for ... 1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2 ...

Sacituzumab Govitecan Versus Docetaxel for Previously Treated ...

Paz-Ares L, Goto Y, Lim WDT, et al: 1194MO canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced ...

Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 ... - MDPI

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III ...

Canakinumab For The Treatment of Amyloidosis Secondary to Lung ...

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): ...

Exploring immune interactions in triple negative breast cancer: IL-1β ...

1194MO canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): ...

how particulate matter pollution is putting the public at risk of lung ...

... canakinumab for atherosclerotic disease. ... Cancer Res 2022; 82: CT037. 12. Paz-Ares L, Goto Y, Lim WDT, et al. 1194MO Canakinumab (CAN). + ...

Identifying shared transcriptional risk patterns between ... - Cell Press

7. Paz-Ares, L. ∙ Goto, Y. ∙ Lim, W.D.T. ... 1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of ...

Identifying shared transcriptional risk patterns between ... - OUCI

Paz-Ares, 1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 ...